Tags

Type your tag names separated by a space and hit enter

Effects of calcium on cardiovascular events in patients with kidney disease and in a healthy population.
Clin J Am Soc Nephrol. 2010 Jan; 5 Suppl 1:S41-7.CJ

Abstract

BACKGROUND AND OBJECTIVES

Cardiovascular disease (CVD) is the largest contributor to all-cause mortality in patients with end stage renal disease (ESRD). Accelerated vascular calcification is a key risk factor for CVD in these patients. The etiology of vascular calcification and the specific role calcium supplementation may play in accelerating calcification have not been fully elucidated.

DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS

We summarize published data that report on the association between calcium supplementation, vascular calcification, and CVD in patients with and without ESRD.

RESULTS

The majority of randomized, controlled trials in patients with ESRD suggest that calcium supplementation--in the form of calcium-based phosphate binders--leads to a progression of vascular calcification. However, studies showing that calcium-based phosphate binders increase cardiovascular mortality are lacking in patients with ESRD. In contrast, one randomized trial in healthy postmenopausal women reported that, compared with those not receiving calcium supplementation, women who take supplements are at an increased risk for cardiovascular events.

CONCLUSIONS

Given the potential for harm with calcium supplementation in healthy postmenopausal women and the evidence that calcium-based phosphate binders are associated with adverse intermediate outcomes in patients with ESRD, calcium-either as a phosphate binder or as a supplement--should be prescribed with caution.

Authors+Show Affiliations

Multidisciplinary Osteoporosis Program, Women's College Hospital, Toronto, Ontario, Canada. sarah.west@utoronto.caNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

20089502

Citation

West, Sarah L., et al. "Effects of Calcium On Cardiovascular Events in Patients With Kidney Disease and in a Healthy Population." Clinical Journal of the American Society of Nephrology : CJASN, vol. 5 Suppl 1, 2010, pp. S41-7.
West SL, Swan VJ, Jamal SA. Effects of calcium on cardiovascular events in patients with kidney disease and in a healthy population. Clin J Am Soc Nephrol. 2010;5 Suppl 1:S41-7.
West, S. L., Swan, V. J., & Jamal, S. A. (2010). Effects of calcium on cardiovascular events in patients with kidney disease and in a healthy population. Clinical Journal of the American Society of Nephrology : CJASN, 5 Suppl 1, S41-7. https://doi.org/10.2215/CJN.05860809
West SL, Swan VJ, Jamal SA. Effects of Calcium On Cardiovascular Events in Patients With Kidney Disease and in a Healthy Population. Clin J Am Soc Nephrol. 2010;5 Suppl 1:S41-7. PubMed PMID: 20089502.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of calcium on cardiovascular events in patients with kidney disease and in a healthy population. AU - West,Sarah L, AU - Swan,Victoria J D, AU - Jamal,Sophie A, PY - 2010/1/22/entrez PY - 2010/2/3/pubmed PY - 2010/4/3/medline SP - S41 EP - 7 JF - Clinical journal of the American Society of Nephrology : CJASN JO - Clin J Am Soc Nephrol VL - 5 Suppl 1 N2 - BACKGROUND AND OBJECTIVES: Cardiovascular disease (CVD) is the largest contributor to all-cause mortality in patients with end stage renal disease (ESRD). Accelerated vascular calcification is a key risk factor for CVD in these patients. The etiology of vascular calcification and the specific role calcium supplementation may play in accelerating calcification have not been fully elucidated. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We summarize published data that report on the association between calcium supplementation, vascular calcification, and CVD in patients with and without ESRD. RESULTS: The majority of randomized, controlled trials in patients with ESRD suggest that calcium supplementation--in the form of calcium-based phosphate binders--leads to a progression of vascular calcification. However, studies showing that calcium-based phosphate binders increase cardiovascular mortality are lacking in patients with ESRD. In contrast, one randomized trial in healthy postmenopausal women reported that, compared with those not receiving calcium supplementation, women who take supplements are at an increased risk for cardiovascular events. CONCLUSIONS: Given the potential for harm with calcium supplementation in healthy postmenopausal women and the evidence that calcium-based phosphate binders are associated with adverse intermediate outcomes in patients with ESRD, calcium-either as a phosphate binder or as a supplement--should be prescribed with caution. SN - 1555-905X UR - https://www.unboundmedicine.com/medline/citation/20089502/Effects_of_calcium_on_cardiovascular_events_in_patients_with_kidney_disease_and_in_a_healthy_population_ L2 - https://cjasn.asnjournals.org/cgi/pmidlookup?view=long&pmid=20089502 DB - PRIME DP - Unbound Medicine ER -